Endometriosis recurrence after surgical excision remains a clinical reality driven by residual ectopic implants, persistent hormonal milieu favoring re-seeding, and incomplete initial resection. NaProTECHNOLOGY addresses recurrence risk through postoperative hormone normalization guided by CrMS biomarkers, with repeat PEARS reserved for symptomatic or fertility-impairing recurrence confirmed by clinical and laparoscopic assessment.
Hilgers TW2004The Medical and Surgical Practice of NaProTECHNOLOGY
Endometriosis impairs fertility through direct mechanical distortion of pelvic anatomy, peritoneal inflammatory mediators, and hormonal micro-environment alterations that reduce implantation potential...
Hilgers TW et al.2004The Medical and Surgical Practice of NaProTECHNOLOGY
Family physicians are optimally positioned to introduce NaProTECHNOLOGY to patients presenting with infertility, irregular cycles, or recurrent pregnancy loss during routine primary care, enabling ear...
Hilgers TW2004The Medical and Surgical Practice of NaProTECHNOLOGY
Chronic pelvic pain and dysmenorrhea in reproductive-age women most commonly reflect undertreated endometriosis, adenomyosis, ovarian dysfunction, or pelvic adhesive disease rather than psychosomatic ...
Hilgers TW2004The Medical and Surgical Practice of NaProTECHNOLOGY
Structured postoperative management following PEARS procedures addresses wound care, pain control, early ambulation, hormonal support, and surveillance for complications including bleeding, infection,...